Nivolumab In Patients With Advanced Hepatocellular Carcinoma (CheckMate 040): An Open-Label, Non-Comparative, Phase 1/2 Dose Escalation And Expansion Trial

·2017·DOI
Health Sciences and Innovation
Biological Machine Learning
Cancer Research and Treatment
Cancer Immunotherapy Advances

Role in the Field

Neutralin Health Sciences and Innovation
Neutralin Biological Machine Learning
Neutralin Cancer Research and Treatment
Neutralin Cancer Immunotherapy Advances

Abstract

Citations

3,183

Year

2017

PageRank

3.9 / 10

Relative influence (log-scaled)

Nivolumab In Patients With Advanced Hepatocellular Carcinoma (CheckMate 040): An Open-Label, Non-Comparative, Phase 1/2 Dose Escalation And Expansion Trial | Manumap